Virpax Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology (MET)Posted by On

BERWYN, Pa.–(BUSINESS WIRE)– #pharma–Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, announced today that the Company has completed FDA required preclinical toxicology studies for its licensed Molecular Envelope Technology (MET). MET enhances the delivery of Virpax’s non-addictive pain product an

Source link


Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.